The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|October 14, 2011
Online access to latest application solutions
Shimadzu has launched two new tools giving online access to latest application solutions: a Special Edition of the customer magazine Shimadzu-News specifically for the needs of the pharmaceutical industry, and a News App for iPhone®and iPod® touch featuring the Shimadzu-News.
Advertisement
Shimadzu has launched two new tools giving online access to latest application solutions: a Special Edition of the customer magazine Shimadzu-News specifically for the needs of the pharmaceutical industry, and a News App for iPhone® and iPod® touch featuring the Shimadzu-News.
The 40 page Shimadzu News Pharma Special introduces solutions and applications for a multitude of topics such as drug research, development and testing as well as method development, manufacturing and quality control. The in-depth articles cover many disciplines of analytical instrumentation, e.g. chromatography, TOC and spectroscopy.
Shimadzu Pharma News is available for download at
News App for iPhone® and iPod® touch
Users of Apple mobile devices can now contact Shimadzu directly, independent of PC or notebook. Users benefit from an iOS optimized version of the customer magazine Shimadzu News for iPhone and iPod touch that even works on the iPad®. Additional functions such as overviews on markets or product related articles, an internal search function and the ‘MyShimadzu’ section complete the offer.
The News App can be downloaded from the
iPhone®, iPad® and iPod® are registered trademarks of Apple Inc. in the United States and/or other countries.
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement